Blood Cancer Journal - Table of Contents alert Volume 6 February 2016

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 6, February 2016 In this issue Review Original Articles Letters to the Editor Erratum Sign up for e-alerts Web feed Advertisement Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders.The journal has an Impact Factor of 3.467. Explore the benefits of submitting your next research article. Review Top Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia M M Patnaik and A Tefferi Blood Cancer J 2016 6: e393; 10.1038/bcj.2016.5 Abstract | Full Text Original Articles Top Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life H Bower, T M-L Andersson, M Björkholm, P W Dickman, P C Lambert and Å R Derolf Blood Cancer J 2016 6: e390; 10.1038/bcj.2016.3 Abstract | Full Text Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients K M Kortuem, E Braggio, L Bruins, S Barrio, C S Shi, Y X Zhu, R Tibes, D Viswanatha, P Votruba, G Ahmann, R Fonseca, P Jedlowski, I Schlam, S Kumar, P L Bergsagel and A K Stewart Blood Cancer J 2016 6: e397; 10.1038/bcj.2016.1 Abstract | Full Text Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial J J Shah, L Feng, S K Thomas, Z Berkova, D M Weber, M Wang, M H Qazilbash, R E Champlin, T R Mendoza, C Cleeland and R Z Orlowski Blood Cancer J 2016 6: e396; 10.1038/bcj.2016.4 Abstract | Full Text Letters to the Editor Top The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma J S Ham, S J Kim, J Y Choi, S H Hyun, S-K Choi, H S Kim, S H Lim, J Y Lee, S-H Jung, Y H Ko and W S Kim Blood Cancer J 2016 6: e395; 10.1038/bcj.2016.2 Full Text Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study A Lu, Y Fang, X Du, Y Li, Z Cai, K Yu, L Zhao, B Wang, J Wu, Y Cheng, Y Zuo, Y Jia, F Tan, L Ding, J Lu, L Zhang and X Huang Blood Cancer J 2016 6: e400; 10.1038/bcj.2016.8 Full Text KSHV-encoded vIL-6 collaborates with deregulated c-Myc to drive plasmablastic neoplasms in mice T R Rosean, C J Holman, V S Tompkins, X Jing, M D Krasowski, S Rose-John and S Janz Blood Cancer J 2016 6: e398; 10.1038/bcj.2016.6 Full Text Genetic basis of myeloid transformation in familial platelet disorder/acute myeloid leukemia patients with haploinsufficient RUNX1 allele M Sakurai, H Kasahara, K Yoshida, A Yoshimi, H Kunimoto, N Watanabe, Y Shiraishi, K Chiba, H Tanaka, Y Harada, H Harada, T Kawakita, M Kurokawa, S Miyano, S Takahashi, S Ogawa, S Okamoto and H Nakajima Blood Cancer J 2016 6: e392; 10.1038/bcj.2015.81 Full Text MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma P de la Puente, B Muz, A Jin, F Azab, M Luderer, N N Salama and A K Azab Blood Cancer J 2016 6: e399; 10.1038/bcj.2016.7 Full Text Erratum Top Waldenstrom macroglobulinemia: prognosis and management A Oza and S V Rajkumar Blood Cancer J 2016 6: e391; 10.1038/bcj.2015.42 Abstract | Full Text Advertisement Nature Publishing Group offers a free open access funding support service to enable authors to discover and apply for article processing charge funding available to them. Visit our website for further advice on the funding options available, and guidance in approaching funders and institutions, or email openaccess@nature.com for more information.  You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.